← Eichor
Study identifier: NCT07599696 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Speech Amplification Devices for Parkinson Disease: Talker- and Technology-Driven Enhancements

Condition: Parkinson Disease · Atypical Parkinsonism  ·  Sponsor: Michigan State University

PhaseNA
Planned participants100
Who can joinAll sexes, 50 Years to no upper limit
Healthy volunteersNo

About this study

The proposed research aims to investigate the use of speech amplification devices as a potential treatment option for people with Parkinson's disease and related disorders who exhibit hypophonia, a voice disorder that affects over half of those with Parkinson's disease. By characterizing the acoustic and perceptual effects of speech amplification and identifying ways to optimize outcomes through talker- and device-specific enhancements, this project seeks to develop personalized, evidence-based treatment options for hypophonia. The current proposal will move this effort forward by systematically eliciting and modifying speech amplification device output that leverage both behavioral and technological approaches.

This description comes directly from the study's public registry record.

Talk to the study team

Thea Knowles, PhD  ·  517-353-6401  ·  thea@msu.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Michigan State UniversityEast Lansing, Michigan, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07599696